Article Text

Download PDFPDF
Letter
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus—authors' response
  1. Yaron Rotman1,
  2. Arun J Sanyal2
  1. 1Liver and Energy Metabolism Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
  2. 2Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA
  1. Correspondence to Dr Yaron Rotman, Chief, Liver and Energy Metabolism Unit, Liver Diseases Branch, NIDDK, NIH, 10 Center Drive, Building 10, Room 10N248C, MSC 1800, Bethesda, MD 20892-1800, USA; rotmany{at}niddk.nih.gov

Statistics from Altmetric.com

We would like to thank Professor Cusi1 for pointing out the omission of the important randomised controlled trial,2 in which he and his colleagues have essentially …

View Full Text

Footnotes

  • Contributors YR and AJS wrote the text jointly.

  • Funding National Institute of Diabetes and Digestive and Kidney Diseases (Intramural Research Program).

  • Competing interests AS: Consultant for Echosens-Sandhil and Sequana.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles